We live in a technologically advanced world where consumers are able to purchase virtually anything, at any time, using online as well as offline stores and services. From finding an item to buying it and getting it delivered straight to their doorstep, purchasing is increasingly done with just the click of a few buttons. The average 21st-century shopper expects to be able to pay for his or her products quickly and easily, whether online or offline.

According to a report by Grand View Research on the point-of-sale market (http://nnw.fm/N6Yea), the global point-of-sale terminals market is expected to reach over $113 billion by the end of 2024. This has been largely put down to the introduction of higher security measures, which has minimized user concerns, along with the evolution of wireless internet, Bluetooth devices, card readers, mobile printers, and many other technologies.

With generations Y and Z showing an increased understanding of technology, users are not only seeking new ways to make their payment process easier, but also quicker. As a result, tech and payment solution companies are creating systems whereby consumers can pay via mobile, contactless, and various other innovative mediums.

Omnichannel payment processing businesses are on the rise, offering customers payment options across a range of sales channels and devices. Net Element, Inc. (NASDAQ: NETE), a technology-driven company specializing in mobile payments and value-added transactional services, offers these options by using powerful tools that take into account the latest in technological innovation and security.

Most recently, the company announced that it will be presenting its new point-of-sale program during its 2017 launch, starting with the annual Northeast Acquirers Association conference (NEAA). The presentation is said to include topics relating to NETE’s point-of-sale solutions, including associated mobile solutions; its Poynt, Unified mPOS, Aptito, and gift card programs; its partnering opportunities; and its try-before-you-buy program.

Net Element, Inc. covers a wide range of omnichannel payment solutions in the United States and Central and Southwestern Asia, and it has established a variety of partnerships across the world, including those with Amex and MasterCard. The company now allows businesses on an international level to accept payments over the phone, on mobile, online, and through point-of-sale terminals.

For more information, visit www.NetElement.com

The ‘2017 Disruptive Growth & Healthcare Conference’, which ran February 15-16 at the Convene at 730 Third Avenue Conference Center in midtown Manhattan, New York, featured some stellar participants, either as presenters or as sponsors. Along with over 60 other firms in a variety of fields related to biotech, IntelliPharmaCeutics International, Inc. (NASDAQ: IPCI) (TSX: I) was on the bill. The Toronto, Ontario-based company was scheduled to introduce its drug delivery technologies and exhibit its leading pipeline candidates.

The ‘2017 Disruptive Growth & Healthcare Conference’ hosted by RHK Capital, which formerly operated as Source Capital Group, was sponsored by leading investor relations and financial services firms, including NetworkNewsWire, a Platinum Sponsor.

With its drug delivery technologies built on the Hypermatrix™ platform, IPCI is targeting billion dollar markets. The company’s extended release (ER) (XR) formulations provide mechanisms to slowly dissolve and release constant amounts of a medication over time. Instead, of a patient having to take a pill three times a day, with the risk of losing count or forgetting, one daily dose will improve efficacy. Closer compliance with prescription rules results in better therapy.

ER formulations, widespread for leading indications, are expanding to new drugs. Medications that benefit from the IPCI technology include Oxycodone XR, Dexmethylphenidate ER, Venlafaxine ER, Desvenlafaxine ER, Levetiracetam ER, Lamotrigine ER and Pregabalin. Together, these pharmaceuticals present a market opportunity that exceeds $9 billion.

But a bigger prize is the market for abuse deterrent formulations (ADF), which attempt to fight prescription drug abuse by increasing the difficulty of inappropriate use of opioid medications. In the U.S., opioid abuse is on the rise. Data published by the American Society of Addiction Medicine reveals that in 2015 there were 21,101 deaths caused by opioid overdose. Opioids include licit substances such as codeine, fentanyl, hydrocodone and oxycodone, and illicit ones such as heroin and opium. This is a market estimated to be about $60 billion.

Apart from having its eye on these two lucrative opportunities, IPCI has a growing pipeline of new candidates that may lead to New Drug Application (NDA) and Abbreviated New Drug Application (ANDA) filings. An NDA is filed when a sponsor believes there is enough evidence on a new drug’s safety and effectiveness to support FDA approval to bring it to market. An ANDA is required for generic drugs that are bioequivalent to a drug already being marketed.

IPCI has two novel NDA candidates, Rexista® and Regabatin XR™. Earlier this month, the company announced it had filed a New Drug Application (NDA) seeking authorization to market its Rexista™ abuse-deterrent oxycodone hydrochloride extended release tablets in the 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg and 80 mg strengths.

The FDA has determined that the company’s application is sufficiently complete to permit a substantive review, and has set a target action date under the Prescription Drug User Fee Act (PDUFA) of September 25, 2017. IPCI was able to demonstrate that Rexista™ is bioequivalent to OxyContin® (oxycodone hydrochloride extended release). With this upcoming milestone, IPCI will be setting another marker on its journey to success.

Founded in 1998 by the husband and wife team of Dr. Isa Odidi and Dr. Amina Odidi, IPCI has come a long way. The company now specializes in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals.

Based on this technology platform, Intellipharmaceutics has developed several drug delivery systems and a pipeline of products in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain.

For more information, visit www.Intellipharmaceutics.com

Auxilio, Inc. (NYST MKT: AUXO) is one of a select number of businesses headquartered in Mission Viejo, a mainly residential city in Orange County, California, and a closer look at this small yet booming business shows that it is unique not only for where its offices are based, but also for its value proposition.

Auxilio offers managed print services exclusively to the U.S. health care industry. A leader in this sector due to its innovative and customer-driven approach, Auxilio takes full responsibility for its health care clients’ on-site print environment through situation assessment, process analysis, strategy development and program implementation. The company also works closely with hospitals and hospital systems to deliver quality patient care and accomplishes this objective by providing a customized, scalable document solutions strategy that analyzes, remediates and manages document and print workflows from start to finish.

A vendor-independent company, Auxilio provides intelligent solutions, a risk-free program and guaranteed savings. It assumes all costs related to the print business environment by customizing, streamlining and seamlessly integrating its services at predictable fixed rates that are unmatched in the industry. As a result, its print management programs drive out costs, increase employee productivity and exceed patient care standards, and the hospitals and health systems that work with the company benefit from its streamlined and aligned processes and infrastructure.

For over 10 years, more than 200 of the leading hospitals and health systems in the U.S. have turned to Auxilio to resolve their broken document and digital workflow processes, and its document solutions have helped them reduce waste, safeguard protected health information (PHI) and improve operational efficiency while driving incredible cost savings. The company consistently delivers for its clients by leveraging its three core services lines: Managed Print Services, Document Consulting and iPLATFORM, an intelligent workflow automation suite.

According to the Orange County Business Journal’s 2016 Special Report (http://dtn.fm/C0x5k), from 2014 to 2016, Auxilio clocked more than 40% in growth, making it one of the fastest-growing public companies in the Orange County area. During this time, the company grew its existing business by continuously delivering excellent customer service, and it diversified into cyber security by acquiring two information technology security firms. The resulting demand for Auxilio’s cyber security services and rapid adoption of its Managed Print Services program by many large health care institutions contributed significantly to its recent swift growth.

For more information, visit www.AuxilioInc.com

Colorado-based New Age Beverages Corp. (NASDAQ: NBEV) has priced an underwritten public offering valued at approximately $15 million in gross proceeds and listing on the NASDAQ Capital Market, per a recent press release (http://dtn.fm/E8gLm). The corporation has also granted underwriters an additional opportunity to purchase 642,857 more shares of common stock. This 45-day option will enable them to purchase the extra shares to cover over-allotments. The total gross proceed amount is an estimate before underwriting discounts, commissions, and other offering expenses are deducted.

The company has already filed a registration statement with the Securities and Exchange Commission (SEC). Effective as of February 13, 2017, the filing relates to the securities now being offered. Acting as joint book-running managers are Aegis Capital Corp. and Maxim Group LLC. The recently issued offering will be made only by prospectus, a legal document that must be filed with the SEC, which is available by contacting New Age Beverages Corp. or by visiting the SEC website.

Founded in 2003, New Age Beverages Corp. markets several famous brands of beverages, such as XingTea®, Búcha® Live Kombucha, and Aspen Pure® Rocky Mountain Water. Marley Mellow Mood® Relaxation Drinks and Marley One Drop® Coffee are other products marketed by the company, following the signing of a management agreement in October 2016. The company is now competing in the health and functional beverage segment, a fast-growing area of the beverage market, and sells its brands in all 50 U.S. states. Its brands are also sold internationally, in over 10 countries, across all channels. Some have even gained notoriety. XingTea® recently beat over 250 competitors to earn the title of the ‘#1 Best Tasting Tea’ at the North American Tea Championship.

One of the largest independent distributors in the country, New Age Beverages Corp. reaches over 20,000 outlets from its distribution network in Colorado. It distributes over 60 different brands, representing over 600 SKUs of non-alcoholic and alcoholic beverages, snacks and specialty products. These include the all-natural, non-GMO Xing Energy drink. The employee-owned company recently merged with Marley Beverage Company, which was created in partnership with Bob Marley’s family and is a business that has become reputable in its own right. New Age Beverages Corp. is led by Chief Executive Officer Brent Willis. He has over 20 years of General Management, C-Level, and Board experience and has worked with the Coca-Cola Company (NYSE: KO), Kraft Heinz Company (NASDAQ: KHC), and other global leaders. The company has leveraged an organizational structure focused on testing product innovations, finding emerging products and segments early, and gaining credibility with national distributors.

New Age Beverages Corp. also distributes leading brands such as Nestea®, Nestle Nesquik®, Welch’s, and V8®, among a wide range of others. It understands the value of choosing healthy products. Focused on thinking big, changing the world, teamwork, and execution, the company delivers products that taste good and are affordable for retailers and consumers.

To find out more information, visit www.NewAgeBev.us

The Singing Machine Company, Inc. (OTCQX: SMDM) recorded revenue growth of 9% to $49.3 million for the nine months ended December 31, 2016, compared to $45.2 million for the comparable period in 2015 (http://dtn.fm/j9NfF). For the quarter ended December 31, 2016, sales dropped to $16.3 million compared to $20.7 million during the same period of the prior year. The company said that drop was due to the timing of shipments, which occurred earlier in 2016 than the prior year.

Singing Machine makes a line of karaoke products, offering the consumer access to some 1,300 songs. The music can either be downloaded or streamed. The Singing Machine home line is available in North America or internationally through mass merchant and online retailers. The company is also entering the toy business with Singing Machine Kids (http://dtn.fm/QyN7U), a range of 11 new products for children from preschool through elementary school. The line of sing-a-long products is being shown for the first time to buyers at the New York Toy Fair, February 18-21, 2017.

The company’s net income jumped 3.9% for the nine months ended December 31, 2016, to $2,685,561, up from $2,583,460 for the nine months ended December 31, 2015. For the three months ended December 31, 2016, sales dropped 21% to $16,319,804 compared to $20,667,069 for the comparable period the prior year. Similarly, net income dropped 35% to $1,312,158 for the three months ended December 31, 2016, from $2,006,913 during the same three-month period of the prior year.

Gary Atkinson, Singing Machine CEO, said, “This fiscal year we’ve grown net sales by 9% over last year and we’ve grown pre-tax net income by 33% to $4 million. On the product roadmap, we significantly expanded our distribution of our Digital Download Line of products and saw impressive growth in both downloading and streaming subscriptions.”

Bernardo Melo, VP of Sales, commented that ecommerce has grown to more than 18% of company sales. He said the company enjoyed an average 88% sell-thru across major retailers on both Black Friday and the Christmas season.

The company is unveiling its Singing Machine Kids line and will also, through its partnership with Stingray, offer a karaoke Sing-Along mobile app to be available in the fall. The app, available for both iOS and Android devices, will complement the Singing Machine Kids line.

The toy product line consists of 11 items, including:

• Bluetooth Recording Studio, a portable studio with six sound effects loaded in advance.
• Mic Guy Bluetooth Sing-Along, a battery operated system designed for the littlest singers.
• Candy House Sing-Along, a joyful speaker system with a colored lit roof top.
• Blackboard Calculator, designed to make math interactive and fun with the Wise Old Owl.

“We’re incredibly proud of our new kids line,” commented CEO Atkinson. “Not only have we designed a range of products that will enhance our mission of spreading joy through music, we have also created products that will help kids with a variety of early learning and developmental skills.”

For more information, visit www.SingingMachine.com

ORhub, Inc. (OTC: ORHB), is a cloud-based health care software-as-a-service company whose primary aim is to improve the outcome and reduce costs of surgical care in a variety of hospitals and health care institutions in the United States.

Because many hospitals still rely on paper documentation to track everything that occurs during an operation, there is more space for mistakes, missing information, delays, and payment problems, as well as, generally, less opportunity to effectively improve procedures. ORhub’s digital platform eliminates a variety of the limitations and problems inherent with paper documentation.

Aside from reducing potential mistakes, the platform creates automatic records, streamlines tasks to save time, and enables rich data analysis across all of the hospital’s cases. This allows health care institutions to more easily determine whether comparable surgeries cost the same, the types of implants needed and how they are used, and any inventory that needs to be restocked.

In recent news, the company went through a merger (http://dtn.fm/3bllA) between MemReg, Inc. and ORhub, Inc., with MemReg formally changing its name and ticker symbol to align with its new identity. It’s part of a process to put together initiatives for improving liquidity, strengthening brand recognition, and preparing for future listing on a senior exchange.

Most recently, the company expanded its pilot program (http://dtn.fm/kO4H7) to include one of the top five highest-volume orthopedic hospitals in America. This hospital has been given a five-star rating by the U.S. Centers for Medicare and Medicaid and has been ranked as one of the best orthopedic hospitals in the country two years in a row by U.S. News & World Report. In addition, it is the highest volume provider of joint replacements in California, according to California’s Office of Statewide Health Planning and Development (OSHPD), and is one of only eight hospitals in the state to be classified as a “Highest-Rate Hospital” for knee and hip surgery in 2016 by Consumer Reports.

In a news release, Chief Technology Officer Wesley Mitchell commented, “Our goal is to cut $250 billion out of annual U.S. health care spending by reducing cost and increasing efficiency in surgical operations, which is roughly one-third of the $3 trillion spent on health care in the U.S. every year. Moving forward with one of the most efficient hospitals in the nation gives us a platform to show that what we are doing can have a significant impact at any hospital, even one already praised for its efficiency.”

For more information, visit the company’s website at www.ORhub.com

Net Element (NASDAQ: NETE), in a series of three 8K SEC filings from January 19, 2017, through February 8, 2017 (www.netelement.com/en/ir), has presented to Esousa Holdings, LLC purchase notices aggregating $1.35 million for 1,578,877 shares of its common stock at a price per share ranging from $0.83 to $0.861.

Net Element is a technology provider with a platform that integrates mobile and transactional services. Aptito is its point-of-sale brand, which is cloud-based. Its TOT Group subsidiary also handles transaction processing in the U.S. through Unified Payments. TOT Money is its Russia-based mobile payments provider. Net Element serves the restaurant, retail and travel industries, among others.

The company announced last year a $10 million stock purchase agreement with Esousa Holdings, LLC to provide liquidity. The most recent filings included an 8K on January 19, 2017, issuing a purchase notice to Esousa totaling $200,000 for 240,964 shares at $0.83 per share. Net Element issued another 8K on January 25, 2017, with a purchase notice to Esousa at $150,000 for 176,471 shares at $0.85 per share. Another 8K followed on February 8, 2017, specifying a purchase price of $1 million for 1,161,442 shares at $0.861 per share.

SeeThruEquity, an equity research firm, in December 2016 issued an update note to its report on Net Element and adjusted its target price per share to $2.45. In the revision, the research company expressed optimism about Net Element’s revenue growth of 10% year-over-year in 3Q16 to $14 million, up from $12.7 million in 3Q15.

At the same time, SeeThruEquity noted that Net Element had liabilities on its balance sheet of $16.8 million, inclusive of $4.2 million of financial debt. “We continue to see the balance sheet as an area to watch for NETE, as access to capital has been a swing factor in the performance of the stock,” it said, noting that Net Element has managed to grow but requires capital to finance its aggressive strategy. It noted Net Element’s $10 million stock purchase agreement (SPA) with Esousa Holdings, LLC.

In that July 6, 2016, agreement, Net Element stated that the use of any proceeds would be for working capital and general corporate purposes. The SPA has a 30-month term from its initial date. Among its terms, Net Element can present purchase notices to Esousa to buy an aggregate total of $10 million of its common stock at prices per share to be determined by the NASDAQ market.

For more information, visit www.NetElement.com

Attendees at the Conference on Retroviruses and Opportunistic Infections (February 13-16) at the Washington State Convention Center in Seattle received a two-year update on CytoDyn’s PRO 140 as a single-agent maintenance therapy for HIV-1 infection. The poster presentation was from Dr. Kush Dhody, Senior Director, Clinical Operations at Amarex Clinical Research, on behalf of CytoDyn Inc. (OTCQB: CYDY). A follow-up discussion reviewing five abstracts, hosted by Karl Salzwedel of the National Institutes of Health and under the theme ‘I Want a New Drug’, is also scheduled and expected to feature a panel of distinguished participants, including CytoDyn CEO Nader Pourhassan.

PRO 140 has, so far, demonstrated a remarkable efficacy in HIV therapy, with its unique characteristics as a fully humanized immunoglobulin (Ig) G4 monoclonal antibody. Antibodies are Y-shaped proteins used by the immune system as a first line of defense against pathogens, such as bacteria and viruses. Each antibody is uniquely created to counter a specific antigen, which it then counters by flagging the intruder as such, to be destroyed by microphages, or by neutralizing it.

Vaccines use this response of the human immune system to build a shield against diseases like polio, smallpox, and a host of others. By injecting a small amount of the germ into the body, the antibodies specific to those antigens develop and are on hand to fight off subsequent attack from the infection. However, the science behind PRO 140 is based on monoclonal antibodies.

Monoclonal antibodies are antibodies engineered in the lab to serve as substitutes that can restore, enhance, or mimic the immune system’s attack on pathogenic cells, and they have been developed, to a large extent, for treating cancer patients. Now, PRO 140 is bringing aspects of that technology to the fight against HIV/AIDS while being tested in animals to explore cancer and other non-HIV indications.

Since PRO 140 is a humanized antibody, it is likely to have fewer side effects than a synthetic drug. Humanized antibodies are antibodies from non-human species that have been modified to ‘look like’ human antibodies.

In comments about its science (http://nnw.fm/vDcZ4), CytoDyn notes: “Monoclonal antibodies have come to represent one of the fastest expanding opportunities in the biotechnology/pharma sector. The ability to transition from research reagents generated in mice to fully humanized structures suitable for clinical and commercial development has provided some of the most effective and largest selling therapeutics over the last 10 years.”

On January 11, CytoDyn announced it had filed a request with the FDA for Breakthrough Therapy Designation for PRO 140 as a treatment for HIV-1 infection in treatment-experienced patients with virologic failure. Just the month before, the company announced the first Phase III clinical trial with PRO 140 as a single-agent maintenance therapy in virally suppressed subjects with HIV.

PRO 140 is considered one of the most advanced experimental monoclonal antibodies for HIV treatment, and has been used in more than 140 HIV-infected subjects in placebo controlled and open label FDA-approved clinical trials. The drug has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects and has been designated a “fast track” product candidate by the FDA.

For more information, visit www.CytoDyn.com

A SeeThruEquity report released in February revealed that ChineseInvestors.com, Inc. (OTCQB: CIIX), a specialized investment services company targeting primarily the Chinese-speaking population in the U.S., has made several investments in the global cannabis industry, increasing its growth potential. Still in the early stages of market penetration, the company cited significant potential in its legal cannabis initiatives. Catalysts for potential future growth include a current stake in Medicine Man Technologies, Inc. (OTCQB: MDCL), a business with cultivation, production, and dispensary operations, which has already generated proceeds from stock sales.

The company’s recent achievements include completing a $5 million private placement of Series C-2016 convertible preferred stock, per a NetworkNewsWire release (http://dtn.fm/SEd6L). Revenue growth was reported for three consecutive quarters as the company was preparing to expand sales in the United States and China through a new website. Revenues were significantly higher over three- and six-month periods ended November 30, 2016, as operating revenues increased by 133% and 121% over those respective time frames. Long term plans include opening physical retail stores in the United States and elsewhere around the globe.

In January, the company launched its cannabidiol (CBD) health products store online, noted as the first of its kind in the Chinese language. The website www.ChineseCBDoil.com sells CBD-containing nutritional supplements and provides a portal for retail destinations to sell products in-store. Extracted from cannabis, CBD oil is non-toxic and non-addictive and is being increasingly accepted for its medicinal properties. Potential has been seen in the treatment of conditions such as anxiety and stress, epilepsy, Alzheimer’s disease, and cirrhosis of the liver. In addition, the company plans to launch a mobile app for locating cannabis dispensaries and discussing related products in the U.S. This follows a December 2016 announcement (http://dtn.fm/K61pa) that it had formed an alliance with Shenzhen Yuanrong PE Capital, a private equity firm, to pursue medical/recreational cannabis business opportunities.

SeeThruEquity sees ChineseInvestors.com, Inc. as a high-risk/high-reward investment opportunity, with potential for further growth if there is renewed traction with its investor relations services businesses. The company reported revenue had reached $510,944 in the second quarter of fiscal year 2017, an increase from the August quarter revenue of $341,324. Also, it reported $1.4 million in assets and $636,345 in available cash during the first two quarters of fiscal 2017.

ChineseInvestors.com, Inc. was founded in 1999, in Colorado, to serve the U.S. Chinese-speaking population with stock market data and investment information. It is led by CEO Warren Wang, who was born in Shanghai, China, and has over 15 years of experience in the financial markets industry. He has worked in management, sales, project management, marketing, and accounting. Quoqi Deng is the company’s CFO and previously worked with the Shenyang Technological Development Zone for 12 years, introducing billions in overseas capital to fund a major construction project in China. The company aims to inform individual investors so they can make financial decisions and achieve their goals. It uses an investment method that integrates support, web-based tools, a disciplined investing process, and personalized instructions to foster self-direction and life-long learning among investors.

For more information, visit the company’s website at www.ChineseInvestors.com

ORHub, Inc. (OTC: ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient’s outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today’s siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub’s leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company’s business strategy. Mr. Melby’s extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care.

For more information, visit the company’s website at www.ORHub.com